The Estrogen Receptor: A Logical Target for the Prevention of Breast Cancer with Antiestrogens (original) (raw)

REFERENCES

  1. G. T. Beatson (1896). On the treatment of inoperable cases of carcinoma of the mamma: Suggestions for a new method of treatment with illustrative cases. Lancet **ii:**104–107; 162–167.
    Google Scholar
  2. S. Boyd (1900). On oophorectomy in cancer of the breast. Brit. Med. J. **ii:**1161–1167.
    Google Scholar
  3. M. P. Cole, C. T. A. Jones, and I. D. H. Todd (1971). A new antioestrogenic agent in late breast cancer. An early appraisal of ICI 46, 474. Brit. J. Cancer **25:**270–275.
    PubMed Google Scholar
  4. H. W. C. Ward (1973). Antioestrogenic therapy for breast cancer: A trial of tamoxifen at two dose levels. Brit. Med. J. **ii:**13–14.
    Google Scholar
  5. E. V. Jensen and H. I. Jacobson (1962). Basic guides to the mechanism of estrogen action. Recent Prog. Horm. Res. **18:**387–414.
    Google Scholar
  6. E. V. Jensen, G. E. Block, S. Smith, K. Kyser, and E. R. DeSombre (1971). Estrogen receptors and breast cancer response to adrenalectomy. NCI Monographs **34:**55–70.
    Google Scholar
  7. V. C. Jordan and S. P. Robinson (1987). Species specific pharmacology of antiestrogens: Role of metabolism. Fed. Proc. **46:**1870–1874.
    PubMed Google Scholar
  8. V. C. Jordan, E. Phelps, and J. U. Lindgren (1987). Effects of antiestrogens on bone in castrated and intact female rats. Breast Cancer Res. Treat. **10:**31–35.
    PubMed Google Scholar
  9. M. M. Gottardis and V. C. Jordan (1987). The antitumor actions of keoxifene (raloxifene) and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model. Cancer Res. **47:**4020–4024.
    PubMed Google Scholar
  10. R. T. Turner, G. K. Wakley, K. S. Hannon, and N. H. Bell (1987). Tamoxifen prevents the skeletal effects of ovarian hormone deficiency in rats. J. Bone Min. Res. **2:**449–456.
    Google Scholar
  11. S. Turken, E. Siris, D. Seldin, E. Flaster, G. Hyman, and R. Lindsay (1989). Effects of tamoxifen on spinal bone density in women with breast cancer. J. Natl. Cancer Inst. **81:**1086–1088.
    PubMed Google Scholar
  12. R. R. Love, R. B. Mazess, H. S. Barden, S. Epstein, P. A. Newcomb, V. C. Jordan, P. P. Carbone, D. L. DeMets (1992). Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N. Engl. J. Med. **326:**885–886.
    PubMed Google Scholar
  13. S. Rossner and A. Wallgren (1984). Serum lipoproteins and proteins after breast cancer surgery and effects of tamoxifen. Atherosclerosis **52:**339–346.
    PubMed Google Scholar
  14. R. R. Love, D. A. Wiebe, P. A. Newcomb, L. Cameron, H. Leventhal, V. C. Jordan, J. Feyzi, and D. L. DeMets (1991). Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. Ann. Int. Med. **115:**860–864.
    PubMed Google Scholar
  15. L. J. Lerner, J. F. Holthaus, and C. R. Thompson (1958). A nonsteroidal estrogen antagonist 1–(p-2 diethylaminoeth oxyphenyl)-1–phenyl-2–p-methoxyphenyl-ethanol. Endocrinology **63:**295–318.
    PubMed Google Scholar
  16. L. J. Lerner (1981). The first nonsteroidal antioestrogen — MER 25. In R. L. Sutherland and V. C. Jordan (eds.), Nonsteroidal Antioestrogens: Molecular Pharmacology and Antitumor Activity. Sydney, Academic Press, pp. 1–16.
    Google Scholar
  17. M. J. K. Harper and A. L. Walpole (1967). A new derivative of triphenylethylene: Effect of on implantation and mode of action in rats. J. Reprod. Fertil. **13:**101–119.
    PubMed Google Scholar
  18. G. W. Duncan, S. C. Lyster, J. J. Clark, D. Lednicer (1963). Antifertility activities of two diphenyl-dihydr onaphthalene derivatives. Proc. Soc. Expl. Biol. Med. **112:**439–442.
    Google Scholar
  19. M. R. Callantine, R. R. Humphrey, S. L. Lee, B. L. Windsor, N. H. Schottin, and O. P. O'Brien. (1966). Action of an estrogen antagonist on reproductive mechanisms in the rat. Endocrinology **79:**153–167.
    PubMed Google Scholar
  20. D. E. Holtkamp, S. C. Greslin, C. A. Root, and L. J. Lerner (1960). Gonadotropin inhibiting and antifecundity effects of chloramiphene. Proc. Soc. Expl. Biol. Med. **105:**197–201.
    Google Scholar
  21. V. C. Jordan and L. J. Dowse (1976). Tamoxifen as an antitumor agent: Effect on oestrogen binding. J. Endocrinol. **68:**297–303.
    PubMed Google Scholar
  22. L. Terenius (1971). Antiestrogen and breast cancer. Eur. J. Cancer **7:**57–64.
    PubMed Google Scholar
  23. E. R. DeSombre and L. Y. Arbogast (1974) Effect of the antiestrogen CI628 on the growth of rat mammary tumors. Cancer Res. **34:**1971–1976.
    PubMed Google Scholar
  24. M. E. Lippman, G. Bolan, and K. Huff (1976). The effects of estrogen and antiestrogens on hormone-responsive human breast cancer in long term tissue culture. Cancer Res. **36:**4595–4601.
    PubMed Google Scholar
  25. L. Terenius (1971) Structure-activity relationships of antioestrogens with regard to interaction with 17 β oestradiol in the mouse uterus and vagina. Acta Endocrinol. Suppl. **66:**431–437.
    Google Scholar
  26. S. D. Lyman, and V. C. Jordan (1986). Metabolism of nonsteroidal antiestrogens. In V. C. Jordan (ed.), Estrogen/Antiestrogen Action and Breast Cancer Therapy, Madison UW Press, pp. 191–219.
  27. S. P. Robinson, S. M. Langan-Fahey, and V. C. Jordan (1989). Implications of tamoxifen metabolism in the athymic mouse for the study of antitumor effects upon human breast cancer xenografts. Eur. J. Cancer Clin. Oncol. **25:**1769–1776.
    PubMed Google Scholar
  28. A. S. Levenson, and V. C. Jordan (1997). MCF-7: The first estrogen responsive breast cancer cell line (Perspectives in Cancer Research). Cancer Res. **57:**3071–3078.
    PubMed Google Scholar
  29. C. K. Osborne, K. Hobbs, and G. M. Clark (1985). Effects of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice. Cancer Res. **45:**584–590.
    PubMed Google Scholar
  30. P. G. Satyaswaroop, R. J. Zaino, and R. Mortel (1984). Estrogen-like effects of tamoxifen on endometrial carcinoma transplanted in nude mice. Cancer Res. **44:**4006–4010.
    PubMed Google Scholar
  31. M. M. Gottardis, S. P. Robinson, P. G. Satyaswaroop, and V. C. Jordan (1988). Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Res. **48:**812–815.
    PubMed Google Scholar
  32. A. M. Brzozowski, A. C. W. Pike, Z. Dauter, R. E. Hubbard, T. Bonn, O. Engstrom, L. Ohman, G. L. Greene, J-A. Gustafsson, and M. Carlquist (1997). Molecular basis of agonism and antagonism in the oestrogen receptor. Nature (London) **389:**753–758.
    PubMed Google Scholar
  33. V. C. Jordan (1984). Biochemical pharmacology of antiestrogen action. Pharm. Rev. **36:**245–276.
    PubMed Google Scholar
  34. D. Lednicer, S. C. Lyster, G. W. Duncan (1967). Mammalian antifertitity agents IV Basic 3,4 dihydronaphthalenes and 1,2,3,4–tetrahydro-1–naphthols. J. Med. Chem. **10:**78–86.
    PubMed Google Scholar
  35. E. R. Clark, and V. C. Jordan (1976). Oestrogenic, antioestrogenic and fertility properties of a series of compounds related to ethamoxytriphetol (MER25) Br. J. Pharmacol. **57:**487–493.
    PubMed Google Scholar
  36. D. W. Robertson, J. A. Katzenellenbogen, J. R. Hayes, and B. S. Katzenellenbogen (1982). Antiestrogen basicity-activity relationships: A comparison of the estrogen receptor binding and uterotropic potencies of several; analogs of (Z)-1,2diphenyl-1–[4–[2–(dimethylamino)ethoxyphenyl]but-1–ene(tamoxifen, Nolvadex) having altered basicity. J. Med. Chem. **25:**167–172.
    PubMed Google Scholar
  37. V. C. Jordan, and B. Gosden (1982). Importance of the alkylamino-ethoxyside chain for the estrogenic and antiestrogenic actions of tamoxifen and trioxifene in the immature rat uterus. Mol. Cell Endocrinol. **27:**291–306.
    PubMed Google Scholar
  38. D. M. Wolf and V. C. Jordan (1994). The estrogen receptor from a tamoxifen stimulated MCF-7 tumor variant contains a point mutation in the ligand binding domain. Breast Cancer Res. Treat. **31:**129–138.
    PubMed Google Scholar
  39. W. H. Catherino, D. M. Wolf, and V. C. Jordan (1995). A naturally occurring estrogen receptor mutation results in increased estrogencity for a tamoxifen analog. Mol. Endocrinol. **9:**1053–1063.
    PubMed Google Scholar
  40. A. S. Levenson, D. A. Tonetti, and V. C. Jordan (1998). The oestrogen-like effect of 4–hydroxytamoxifen on induction of transforming growth factor α mRNA in MDA-MB-231 breast cancer cells stably expressing the oestrogen receptor. Brit. J. Cancer **77:**1812–1819.
    PubMed Google Scholar
  41. V. C. Jordan, M. M. Collins, L. Rowsby, and G. Prestwich (1977). A monohydroxylated metabolite of tamoxifen with potent antiestrogenic activity. J. Endocrinol. **75:**305–316.
    PubMed Google Scholar
  42. A. S. Levenson, W. H. Catherino, and V. C. Jordan (1997). Estrogenic activity is increased for an antiestrogen by a natural mutation of the estrogen receptor. J. Steroid Biochem. Mol. Biol. **60:**261–268.
    PubMed Google Scholar
  43. A. S. Levenson and V. C. Jordan (1998). The key to the antiestrogenic mechanism of raloxifene is amino acid 351 (aspartate) in the estrogen receptor. Cancer Res. **58:**1872–1875.
    PubMed Google Scholar
  44. S. Halamichi, E. Marden, G. Martin, H. Mackey, C. Abbondonza, M. Brown (1993). Estrogen receptor associated proteins: Possible mediators of hormone induced transcription. Science **264:**1455–1458.
    Google Scholar
  45. B. Hanstein, R. Eckner, J. DiRenzo, S. Halamichi, H. Liu, B. Searey, R. Kurokawa, and M. Brown (1996). p300 is a component of an estrogen receptor co-activator complex. Proc. Natl. Acad. Sci. U.S.A. **93:**11540–11545.
    PubMed Google Scholar
  46. C. Baniahmad, Z. Nowaz, A. Banaihmad, M. A. G. Gleeson, M-J. Tsui, B. W. O'Malley (1995). Enhancement of human estrogen receptor activity by SPT6: A potential co-activator. Mol. Endocrinol. **9:**34–43.
    PubMed Google Scholar
  47. S. A. Onate, S. Y. Tsai, M-J. Tsai, B. W. O'Malley (1995). Sequence and characterization of a coactivitor for the steroid receptor superfamily. Science **270:**1354–1357.
    PubMed Google Scholar
  48. J. A. Katzenellenbogen, B. W. O'Malley, B.S. Katzenellenbogen (1996). Tripartite steroid receptor pharmocology: Interaction with multiple effector sites as a basis for the cell-and promoter-specific action of these hormones. Mol. Endocrinol. **10:**119–131.
    PubMed Google Scholar
  49. H. Li, and J. D. Chen (1998). The receptor-associated coactivator-3 activated transcription through CREB-binding protein recruitment and autoregulation. J. Biol. Chem. **273:**5948–5954.
    PubMed Google Scholar
  50. Y. Kamei, L. Xu, T. Heinzel, J. Torchia, R. Kurokawa, B. Gloss, S. C. Lin, R. A. Heyman, D. W. Rose, C. K. Glass, and M. G. Rosenfeld (1996). A ABP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors. Cell **85:**403–414.
    PubMed Google Scholar
  51. H. Hong, K. Kohli, A. Trivedi, D. L. Johnson, and M. R. Stallcup (1996). GRIP-1, a novel mouse protein that serves as a transcriptional coactivator in yeast for the hormone binding domains of steroid receptors. Proc. Natl. Acad. Sci. U.S.A. **93:**4948–4952.
    PubMed Google Scholar
  52. J. J. Voegel, M. J. S. Heine, C. Zechel, P. Chambon, and H. Gronemeyer (1996). TIF2, a 160kDa transcriptional mediator for the ligand-dependent activation function AF-2 of nuclear receptors. EMBO J. **15:**3667–3675.
    PubMed Google Scholar
  53. J. Torchia, D. Rose, J. Inostroza, Y. Kamel, S. Westin, C. Glass, and M. Rosenfeld (1997). The transcriptional co-activator p/CIP binds CBP and mediates nuclear-receptor function. Nature **387:**677–684.
    Article PubMed Google Scholar
  54. S. L. Anzick, J. Kononen, R. L. Walker, D. O. Azorsa, M. M. Tanner, X-Y. Guan, G. Sauter, O-P. Kallioniemi, J. M. Trent, and P. S. Meltzer (1997). AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science **277:**965–968.
    Article PubMed Google Scholar
  55. H. Chen, R. J. Lin, R. L. Schiltz, D. Chakravarti, A. Nash, L. Nagy, M. L. Privalsky, Y. Nakatani, and R. M. Evans (1997). Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with P/CAF and CBP/p300. Cell **90:**569–580.
    PubMed Google Scholar
  56. N. J. McKenna, Z. Nawaz, S. Y. Tsai, M-J. Tsai, and B. W. O'Malley (1998). Distinct steady state nuclear hormone receptor coregulator complexes exist in vivo. Proc. Natl. Acad. Sci. U.S.A. **95:**11697–11702.
    PubMed Google Scholar
  57. D. M. Heery, E. Kalkhoven, S. Hoare, and M. G. Parker (1997). A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature **387:**733–736.
    Article PubMed Google Scholar
  58. A. K. Shiau, D. Barstad, P. M. Loria, L. Cheng, P. J. Kushner, D. A. Agard, and G. L. Greene (1998). The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell **95:**927–937.
    PubMed Google Scholar
  59. R. M. L. Zwijsen, R. S. Buckle, E. M. Hijmans, C. J. M. Loomans, and R. Bernards (1998). Ligand-independent recruitment of steroid receptor coactivators to estrogen receptor by cyclin D1. Genes Dev. **12:**3488–3498.
    PubMed Google Scholar
  60. N. J. McKenna, J. Xu, Z. Nawaz, S. Y. Tsai, M-J. Tsai, and B. W. O'Malley, (1999). Nuclear receptor coactivators: Multiple enzymes, multiple complexes, multiple functions. J. Steroid Biochem. Mol. Biol. **69:**3–12.
    PubMed Google Scholar
  61. S. J. Bannister and T. Kouzarides (1996). The CBP co-activator is a histone acetyltransferase. Nature **384:**641–643.
    PubMed Google Scholar
  62. T. E. Spencer, G. Jenster, M. M. Buurcin, C. D. Allis, J. X. Zhou, C. A. Mizzen, N. J. McKenna, S. A. Onate, S. Y. Tsai, M-J. Tsai, and B. W. O'Malley (1997). Steroid receptor coactivator-1 is a histone acetyltransferase. Nature **389:**194–198.
    PubMed Google Scholar
  63. C. L. Smith, Z. Nawaz, and B. W. O'Malley (1997) Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4–hydroxytamoxifen. Mol. Endocrinol. **11:**693–705.
    PubMed Google Scholar
  64. X. Zhang, M. Jeyakumar, S. Petukhov, and M. K. Bagchi (1998). A nuclear receptor corepressor modulates transcriptional activity of antagonist-occupied steroid hormone receptor. Mol. Endocrinol. **12:**513–524.
    PubMed Google Scholar
  65. G. S. Takimoto, J. D. Graham, T. A. Jackson, L. Tung, R. L. Powell, L. D. Horwitz, and K. B. Horwitz. Tamoxifen resistant breast cancer: Coregulators determine the direction of transcription by antagonist-occupied steroid receptors. J. Steroid Biochem. Mol. Biol. **69:**45–50.
  66. M. Berry, D. Metzger, and P. Chambon (1990). Role of the two activating domains of the estrogen receptor in the cell type end promoter context dependent agonist activity of the antioestrogen 4 hydroxytamoxifen EMBO J. **9:**2811–2818.
    PubMed Google Scholar
  67. D. P. McDonnell, D. L. Clemm, T. Herman, M. E. Goldman, and J. W. Pike (1995). Analysis of estrogen receptor function reveals three distinct classes of antiestrogens. Mol. Endocrinol. **9:**659–669.
    PubMed Google Scholar
  68. G. G. Kuiper, E. Enmark, M. Pelto-Huikko, S. Nilsson, and J. A. Gustafsson (1996). Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Proc. Natl. Acad. Sci. U.S.A. **93:**5925–5930.
    PubMed Google Scholar
  69. R. A. Bhat, D. C. Harnish, P. E. Stevis, C. R. Lyttle, and B. S. Komm (1998). A novel human estrogen receptor β: Identification and functional analysis of additional N-terminal amino acids. J. Steroid Biochem. Mol. Biol. **67:**233–240.
    PubMed Google Scholar
  70. S. Ogawa, S. Inoue, T. Watanabe, H. Hiroi, A. Orimo, T. Hosoi, Y. Ouchi, and M. Muramatsu (1998). Biochem. Biophys. Res. Com. **243:**122–126.
    PubMed Google Scholar
  71. S. M. Cowley, S. Hoare, S. Mosselman, and M. G. Parker (1997). Estrogen receptors α and β form heterodimers on DNA. J. Biol. Chem. **272:**19585–19862.
    Google Scholar
  72. P. Pace, J. Taylor, S. Suntharalingam, R. C. Coombes, and S. Ali (1997). Human estrogen receptor β binds DNA in a manner similar to and dimerizes with estrogen receptor α. J. Biol. Chem. **272:**25832–25838.
    PubMed Google Scholar
  73. S. M. Hyder, C. Chiappetta, and G. M. Stancel (1999). Interaction of human estrogen receptors α and β with the same naturally occurring estrogen response elements. Biochem. Pharmacol. **57:**597–601.
    PubMed Google Scholar
  74. S. M. Cowley and M. G. Parker (1999). A comparison of transcriptional activation by ERα and ERβ. J. Steroid Biochem. Mol. Biol. **69:**165–175.
    PubMed Google Scholar
  75. T. Barkhem, B. Carlsson, Y. Nilsson, E. Enmark, J-A. Gustafsson, and S. Nilsson (1998). Differential response of estrogen receptor α and estrogen receptor β to partial estrogen agonists/antagonists. Mol. Pharmacol. **54:**105–112.
    PubMed Google Scholar
  76. J. Sun, M. Meyers, B. E. Fink, R. Rajendran, J. Katzenellenbogen, and B. S. Katzenellenbogen (1999). Novel ligands that function as selective estrogens or antiestrogens for estrogen receptor-α or estrogen receptor-β. Endocrinology **140:**800–804.
    PubMed Google Scholar
  77. P. Webb, G. N. Lopez, R. M. Uht, and P. J. Kushner (1995). Tamoxifen activation of the estrogen receptor/AP-1 Pathway: Potential origin for the cell-specific estrogen-like effects of antiestrogens. Mol. Endorinol. **9:**443–456.
    Google Scholar
  78. K. Paech, P. Webb, G. G. Kuiper, S. Nilsson, J. A. Gustafsson, P. J. Kushner, and J. M. Scarlan (1997). Differential ligand activation of estrogen receptor ERα and ERβ at AP-1 sites. Science **277:**1508–1510.
    PubMed Google Scholar
  79. V. Speirs, A. T. Parkes, M. J. Kerin, D. S. Walton, P. J. Carleton, J. N. Fox, and S. L. Atkin, (1999). Coexpression of estrogen receptor α and β: Poor prognostic factors in human breast cancer. Cancer Res. **59:**525–528.
    PubMed Google Scholar
  80. H. Dotzlaw, E. Leygue, P. H. Watson, and L. C. Murphy (1999). Estrogen receptor-β messenger RNA expression in human breast tumor biopsies: Relationship to steroid receptor status and regulation by progestins. Cancer Res. **59:**529–532.
    PubMed Google Scholar
  81. G. G. Kuiper, B. Carlsson, K. Grnadien, E. Enmark, J. Haggblad, S. Nilsson, and J. A. Gustafsson (1997). Comparison of ligand binding specificity and transcript tissue distribution of estrogen receptor α and β. Endocrinology **138:**863–870.
    Article PubMed Google Scholar
  82. E. A. Vladusic, A. E. Hornby, F. K. Guerra-Vladusic, and R. Lupu (1998). Expression of estrogen receptor β messenger RNA variant in breast cancer. Cancer Res. 58: 210–214.
    PubMed Google Scholar
  83. E. Leygue, H. Dotzlaw, P. H. Watson, and L. C. Murphy (1999). Expression of estrogen receptor β1, β2, and β5 messenger RNAs in human breast tissue. Cancer Res. **59:**1175–1179.
    PubMed Google Scholar
  84. B. Hanstein, H. Liu, M. C. Yancisin, and M. Brown (1999). Functional analysis of a novel estrogen receptor-β isoform. Mol. Endocrinol. 13: 129–137.
    PubMed Google Scholar
  85. D. A. Tonetti and V.C. Jordan (1997). The role of estrogen receptor mutations in tamoxifen-stimulated breast cancer. Invited review, J. Steroid. Biochem. Mol. Biol. **62:**119–128.
    PubMed Google Scholar
  86. Early Breast Cancer Trialists' Collaborative Group (1998). Tamoxifen for early breast cancer: An overview of the randomized trials. Lancet **351:**1451–1467.
    Google Scholar
  87. J. I. MacGregor and V. C. Jordan (1998). Basic guide to the mechanisms of antiestrogen action. Pharm. Rev. **50:**151–196.
    PubMed Google Scholar
  88. V. C. Jordan, C. J. Dix, and K. E. Allen (1979). The effectiveness of long term tamoxifen treatment in a laboratory model for adjuvant hormone therapy of breast cancer. In S. E. Salmon and S. E. Jones (eds.), Adjuvant Therapy of Cancer II, Grune and Stratton Inc., pp. 19–26.
  89. V. C. Jordan and K. E. Allen (1980). Evaluation of the antitumour activity of the nonsteroidal antioestrogen monohydroxytamoxifen in the DMBA-induced rat mammary carcinoma model. Eur. J. Cancer **16:**239–251.
    PubMed Google Scholar
  90. V. C. Jordan (1983). Laboratory studies to develop general principles for the adjuvant treatment of breast cancer with antiestrogens: Problems and potential for future clinical applications. Breast Cancer Res. Treat. 3(Suppl.): S73–86.
    PubMed Google Scholar
  91. B. Fisher, J. P. Costantino, D. L. Wickerham, C. Redmond, M. Kovanah, W. M. Cronin, V. Vogel, A. Robidoux, N. Dimitrov, J. Atkins, M. Daly, S. Wiend, E. Tan-Chiu, L. Ford, and N. Wolmark (1998). Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl. Cancer Inst. **90:**1371–1388.
    PubMed Google Scholar
  92. T. J. Powles, J. R. Hardy, S. E. Ashley, G. M. Farrington, D. Cosgrove, J. B. Dovey, M. Dowsett, J. A. McKinna, A. G. Nash, H. D. Sinnett, C. R. Tillyer, J. G. Treleaven (1989). A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer. Brit. J. Cancer **60:**126–133.
    PubMed Google Scholar
  93. U. Veronesi, P. Maisonneuve, and A. Costa (1998). Prevention of breast cancer with tamoxifen: Preliminary findings from the Italian randomized trial among hysterectomized women. Lancet **362:**93–97.
    Google Scholar
  94. M. H. Gail, L. A. Brinton, and D. P. Byar (1989). Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J. Natl. Cancer Inst. **81:**1879–1886.
    PubMed Google Scholar
  95. T. J. Powles, R. Eeles, S. E. Ashley, D. Easton, J. Chang, M. Dowsett, V. A. Tidy, J. Viggers, J. B. Davey (1998). Interim analysis of the incident breast cancer in the Royal Marsden Hospital tamoxifen randomized chemoprevention trial. Lancet **362:**98–101.
    Google Scholar
  96. C. D. Jones, M. G. Jevnikar, A. J. Pike, M. K. Peters, L. J. Black, A. R. Thompson, J. F. Falcone, and J. A. Clemens (1984). Antiestrogens 2 Structure-activity studies in a series of 3 aroyl-2–arylbenzo[b]thiophene derivatives leading to [6–hydroxy-2–(4–hydrotyphenyl) benzo[b] thiene-3–yl] [4–[2–(1–piperidinyl) ethoxy]-phenyl] methanone hydrochloride (LY156758), a remarkably effective estrogen antagonist with only minimal estrogenicity. J. Med. Chem. **27:**1057–1066.
    PubMed Google Scholar
  97. A. U. Buzdar, C. Marcus, F. Holmes, V. Hug, and G. Hortobagyi (1988). Phase II evaluation of LY156758 in metastatic breast cancer. Oncology **45:**344–345.
    PubMed Google Scholar
  98. W. J. Gradishar, J. E. Glusman, C. L. Vogel, J. L. Mansi, N. S. A. Stuart, J. Carmichael, D. Elling, K. R. Kunz, G. W. Sledge (1997). Raloxifene HC1 a new endocrine agent is active in estrogen receptor positive metastatic breast cancer. Breast Cancer Res. Treat. **46:**53 Abstract #209.
    Google Scholar
  99. J. A. Clemens, D. R. Bennett, L. J. Black, and C. D. Jones (1983). Effects of new antiestrogen keoxifene LY156758 on growth of carcinogen-induced mammary tumors and on LH and prolactin levels. Life Sci. **32:**2868–2875.
    Google Scholar
  100. M. A. Anzano, C. W. Peer, J. M. Smith, L. T. Mullen, M. W. Shrader, D. L. Logsdon, C. L. Driver, C. C. Brauen, A. B. Robert, and M. B. Sporn (1996). Chemoprevention of mammary carcinogenesis in the rat: Combined use of raloxifene and 9–_cis_-retinoic acid. J. Natl. Cancer Inst. **88:**123–125.
    PubMed Google Scholar
  101. L. J. Lerner and V. C. Jordan (1990). Development of antiestrogens and their use in breast cancer. B.F. Cain Memorial Lecture. Cancer Res. **50:**4177–4189.
    PubMed Google Scholar
  102. S. R. Cummings, S. Eckert, K. A. Krueger, D. Grady, T. J. Powles, J. A. Cauley, L. Norton, T. Nickelsen, N. H. Bjarnason, M. Morrow, M. E. Lippman, D. Black, J. E. Glusman, A. Costa, and V. C. Jordan (1999). The effect of raloxifene on risk of breast cancer in postmenopausal women: Results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA **281:**2189–2197.
    PubMed Google Scholar
  103. V. C. Jordan, J. E. Glusman, S. Eckert, M. E. Lippman, T. J. Powles, A. Costa, M. Morrow, and L. Norton (1998). Raloxifene reduces incident primary breast cancers. Intergrated data from multicenter double blind, placebo controlled randomized trials in postmenopausal women. Breast Cancer Res. Treat. **50:**227 Abstract #2.
    PubMed Google Scholar
  104. A. Lacassagne (1936). Hormonal pathogenesis of adenocarcinoma of the breast. Am J. Cancer **27:**217.
    Google Scholar
  105. M. B. Sporn (1976). Approaches to prevention of epithelial cancer during the preneoplastic period. Cancer Res. **36:**2699–2702.
    PubMed Google Scholar
  106. V. C. Jordan (1988). Chemosuppression of breast cancer with tamoxifen: Laboratory evidence and future clinical investigations. Cancer Invest. **6:**589–595.
    PubMed Google Scholar

Download references